Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Changes in Neuronal Oscillations Accompany the Loss of Hippocampal LTP that Occurs in an Animal Model of Psychosis.

Kalweit AN, Amanpour-Gharaei B, Colitti-Klausnitzer J, Manahan-Vaughan D.

Front Behav Neurosci. 2017 Mar 8;11:36. doi: 10.3389/fnbeh.2017.00036. eCollection 2017.

2.

Microglia in Alzheimer's disease.

Li Y, Tan MS, Jiang T, Tan L.

Biomed Res Int. 2014;2014:437483. doi: 10.1155/2014/437483. Epub 2014 Aug 14. Review.

3.

Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability.

Tatard-Leitman VM, Jutzeler CR, Suh J, Saunders JA, Billingslea EN, Morita S, White R, Featherstone RE, Ray R, Ortinski PI, Banerjee A, Gandal MJ, Lin R, Alexandrescu A, Liang Y, Gur RE, Borgmann-Winter KE, Carlson GC, Hahn CG, Siegel SJ.

Biol Psychiatry. 2015 Mar 15;77(6):556-68. doi: 10.1016/j.biopsych.2014.06.026. Epub 2014 Jul 18.

4.

Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.

Gill KM, Cook JM, Poe MM, Grace AA.

Schizophr Bull. 2014 Mar;40(2):341-50. doi: 10.1093/schbul/sbt236. Epub 2014 Jan 24.

5.

Is schizophrenia a dopamine supersensitivity psychotic reaction?

Seeman MV, Seeman P.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:155-60. doi: 10.1016/j.pnpbp.2013.10.003. Epub 2013 Oct 12. Review.

6.

Biomarker investigations related to pathophysiological pathways in schizophrenia and psychosis.

Chana G, Bousman CA, Money TT, Gibbons A, Gillett P, Dean B, Everall IP.

Front Cell Neurosci. 2013 Jun 26;7:95. doi: 10.3389/fncel.2013.00095. eCollection 2013.

7.

Abnormal striatal dopamine transmission in schizophrenia.

Brunelin J, Fecteau S, Suaud-Chagny MF.

Curr Med Chem. 2013;20(3):397-404. Review.

8.

Illicit drug use in heavy smokers with and without schizophrenia.

Mackowick KM, Heishman SJ, Wehring HJ, Liu F, McMahon RP, Kelly DL.

Schizophr Res. 2012 Aug;139(1-3):194-200. doi: 10.1016/j.schres.2012.04.012. Epub 2012 May 14.

9.

Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride.

Ikoma Y, Watabe H, Hayashi T, Miyake Y, Teramoto N, Minato K, Iida H.

J Cereb Blood Flow Metab. 2010 Mar;30(3):663-73. doi: 10.1038/jcbfm.2009.239. Epub 2009 Nov 11.

10.

A dual-hit animal model for age-related parkinsonism.

Boger HA, Granholm AC, McGinty JF, Middaugh LD.

Prog Neurobiol. 2010 Feb 9;90(2):217-29. doi: 10.1016/j.pneurobio.2009.10.013. Epub 2009 Oct 21. Review.

11.

Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects.

Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, Anderson S, Dawant B, Zald D, Meltzer HY.

Biol Psychiatry. 2009 Jun 15;65(12):1024-31. doi: 10.1016/j.biopsych.2008.12.029. Epub 2009 Feb 28.

12.

The nigrostriatal dopamine system of aging GFRalpha-1 heterozygous mice: neurochemistry, morphology and behavior.

Zaman V, Boger HA, Granholm AC, Rohrer B, Moore A, Buhusi M, Gerhardt GA, Hoffer BJ, Middaugh LD.

Eur J Neurosci. 2008 Oct;28(8):1557-68. doi: 10.1111/j.1460-9568.2008.06456.x.

13.

A review of the discovery, pharmacological characterization, and behavioral effects of the dopamine D2-like receptor antagonist eticlopride.

Martelle JL, Nader MA.

CNS Neurosci Ther. 2008 Fall;14(3):248-62. doi: 10.1111/j.1755-5949.2008.00047.x. Review.

14.

Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.

Palmer AA, Brown AS, Keegan D, Siska LD, Susser E, Rotrosen J, Butler PD.

Brain Res. 2008 Oct 27;1237:62-74. doi: 10.1016/j.brainres.2008.07.089. Epub 2008 Jul 30.

15.

A new multi-gram synthetic route to labeling precursors for the D(2/3) PET agent 18F-fallypride.

Kim K, Miller NR, Sulikowski GA, Lindsley CW.

Bioorg Med Chem Lett. 2008 Aug 15;18(16):4467-9. doi: 10.1016/j.bmcl.2008.07.065. Epub 2008 Jul 20.

16.

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.

Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S.

Schizophr Bull. 2008 Jan;34(1):60-71. Epub 2007 Oct 8. Review.

17.

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA.

Schizophr Bull. 2007 Sep;33(5):1120-30. Epub 2007 Jul 19. Review.

18.

Dopamine genes and schizophrenia: case closed or evidence pending?

Talkowski ME, Bamne M, Mansour H, Nimgaonkar VL.

Schizophr Bull. 2007 Sep;33(5):1071-81. Epub 2007 Jul 14. Review.

19.

Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease.

Besret L, Kendall AL, Dunnett SB.

J Anat. 2000 May;196 ( Pt 4):597-607. Review.

20.

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D.

Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74.

Supplemental Content

Support Center